OncoMed's rosmantuzumab lacks clinical benefit in Phase I for solid tumors

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said IV rosmantuzumab (OMP-131R10) every two weeks

Read the full 116 word article

User Sign In